ABIOMED

Company Snapshot

Founded: 1981
Entity Type: Private
Region: U.S.
Revenue: $0 Select
Headquarter: Massachusetts, U.S.
Key Geographics: U.S., Germany, Japan
Corporate Address: 22 Cherry Hill Drive Danvers, Massachusetts 01923 U.S. Tel. +1-978-646-1400 www.abiomed.com

Company Overview

Abiomed is a global medical technology company specializing in developing and manufacturing innovative heart recovery and support systems. Founded in 1981, Abiomed has become a leading player in circulatory support and has transformed the treatment landscape for patients with advanced heart failure. Abiomed was acquired by Johnson & Johnson in 2022.

Abiomed's mission is to provide innovative solutions that restore and sustain heart function, improve patient outcomes, and enhance the quality of life. The company focuses on developing and commercializing advanced medical technologies for circulatory support, emphasizing minimally invasive devices and personalized patient care.

ABIOMED In Reports

Artificial Organs: Global Markets

BCC Market Research Report for Artificial Organs report aims to provide a comprehensive study of the market size Current and historical market revenues can be estimated based on the product type and by region.

Organ and Tissue Transplantation and Alternatives

BCC market research report on global organ and tissue transplantation and alternatives market. Estimation of the market size and analyses of market trends, with data from 2018, 2019 and projection of CAGR through 2024. ...

Surgical Devices Market: A BCC Research Overview

The global surgical devices market should grow from $85.5 billion in 2019 to reach $138.5 billion by 2024 at a compound annual growth rate (CAGR) of 10.1% for the period of 2019-2024.

Company's Business Segments

  • Medical Products : The company provides medical technology for circulatory and oxygenation support, primarily through its Impella heart pumps.

Applications/End User Industries

  • Health Care Professionals
  • Cardiovascular Medical Devices
  • Cardiac Surgery
  • Biotechnology
  • Healthcare
AI Sentiment